Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report

Sarcopenia represents one of the hallmarks of all chronic disease, including non‐small cell lung cancer (NSCLC). A computed tomography scan is an easy modality to estimate the skeletal muscle mass through cross‐sectional image analysis at the level of the third lumbar vertebra (L3). Baseline skeleta...

Full description

Bibliographic Details
Main Authors: Alessio Cortellini, Lucilla Verna, Giampiero Porzio, Federico Bozzetti, Pierpaolo Palumbo, Carlo Masciocchi, Katia Cannita, Alessandro Parisi, Davide Brocco, Nicola Tinari, Corrado Ficorella
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Thoracic Cancer
Subjects:
Immunotherapy
nivolumab
NSCLC
sarcopenia
skeletal muscle
Online Access:https://doi.org/10.1111/1759-7714.12965

Internet

https://doi.org/10.1111/1759-7714.12965

Similar Items